A possible method using baseline hormonal levels to prescribe the appropriate oral therapeutic radioiodine dosage for Graves' disease.

OBJECTIVE: The purpose of this study was to retrospectively examine the correlations of hormonal ratios with radioiodine I-131 therapeutic parameters and the potentiality of prescribing the therapeutic I-131 target dosage for an individual patient with Graves' disease using baseline serum levels of thyroid hormones. MATERIALS AND METHODS: Serum T3, T4, and FT4 levels 6 and 12 months after I-131 therapy/baseline levels (hormonal ratios) were calculated for a total of 68 therapeutic courses in 57 patients with Graves' disease. The therapeutic parameters were absorbed dose (Gy), dose concentration (microCi/g) and oral dose (mCi). Linear regression analysis was performed for correlating hormonal ratios (X) and therapeutic parameters (Y). RESULTS: Significant (P<0.05) negative correlations of the hormonal ratios were observed with absorbed dose (R -0.50 for T3, -0.61 for T4, and -0.46 for FT4 at 6 months, and -0.29 for T3, -0.44 for T4 at 12 months) and dose concentration (R -0.57 for T3, -0.58 for T4, and -0.49 for FT4 at 6 months and -0.27 for T3, -0.27 for T4 at 12 months), but not with oral dose at 6 months and 12 months or the absorbed dose and dose concentration for FT4 at 12 months. The correlations were higher at 6 months than at 12 months and in serum T4 than in serum T3 and FT4. The formulae for serum T4 at 6 months were as follows: Y (Gy)=109-53X and Y (microCi/g)=109-52X. CONCLUSIONS: These results suggest that the hormonal ratios are significantly correlated with the absorbed dose and dose concentration. The formulae for serum T4 at 6 months may serve to prescribe the individual oral dosage for Graves' disease, although the correlation coefficients are about -0.6.

[A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].

A 48-year-old woman noticed her right breast swelling since a few weeks earlier. Rigidity in the AC area, hotness, swelling and peau d'orange appearance of the right whole breast were recognized. She was diagnosed as inflammatory breast cancer clinically and invasive ductal carcinoma with lymphatic invasion pathologically. The patient underwent primary systemic therapy with 4 cycles of CEF (cyclophosphamide 500 mg/m(2), epirubicin 100 mg/m(2), 5-fluorouracil 500 mg/m(2)) followed by 4 cycles of docetaxel (70 mg/m(2)). The effect of chemotherapy showed a partial response evaluated by mammography and ultrasonography, and complete response by MRI before surgery. Right mastectomy with level II lymph node dissection was performed. Pathologically, complete response was confirmed (pCR). Although IBC has been known for its poor outcome, this case suggests IBC will show a better prognosis by chemotherapy such as CEF followed by docetaxel.

99mTc-DTPA-galactosyl-human-serum-albumin liver scintigraphy for evaluating hepatic functional reserve before hepatectomy in a patient with indocyanine green excretory defect: report of a case.

A 78-year-old woman with indocyanine green (ICG) excretory defect underwent left hepatectomy for cystadenocarcinoma. The retention rate of ICG at 15 min (ICGR(15)) was high, at 79.3%, despite all other liver function tests showing normal values. Conversely, 99mTc-DTPA-galactosyl-human-serum-albumin (GSA) liver scintigraphy showed a reduced accumulation of GSA in the left lateral lobe, the hepatic uptake ratio of the GSA scintigraphy was 0.96, and the arterial ketone body ratio was 1.67. Based on these results, we judged that the hepatic functional reserve of this patient was adequate for left hepatectomy, which was subsequently performed uneventfully. Histopathological examination of the resected liver showed neither fibrosis nor inflammatory cell infiltration. Thus, we consider that GSA liver scintigraphy is the best diagnostic modality for evaluating hepatic functional reserve in a patient with ICG excretory defect.

Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy.

UNLABELLED: The purpose of this study was to clarify the characteristic patterns of the thyroid hormonal changes in Graves' disease during the one-year period after 131I therapy considering that few serial hormonal data during this period are available in the literature. METHODS: The levels of serum T3, T4 and FT4 before and during one year were plotted as a function of time in 70 therapy courses of 58 patients without subsequent antithyroid or steroid therapy. RESULTS: 35 euthyroid, 6 hypothyroid and 29 hyperthyroid states were obtained during one year after therapy. Although individual patients had individual hormonal changing patterns, 3 common basic patterns were observed from baseline to one month (early) and thereafter (late), respectively. The early patterns were a decrease in 54 (77%), a minimum change in 8 (11.5%) and an increase in 8 (11.5%). The late patterns were a stable state after an initial decrease with a bottom followed by an increase (valley pattern) in 47 (67%), a stable state after an initial increase with a peak followed by a decrease with a bottom and a subsequent re-increase (mountain pattern) in 12 (17%) and a late stable state after a gradual slow decrease without an obvious bottom near or till one year (downhill pattern) in 11 (16%). The bottom level and the degree of hormonal recovery from the bottom determined the stable euthyroid, hypothyroid or hyperthyroid state in 49 (86%) of 57 with the valley or mountain pattern. Most of the bottom levels (81%) and transient abnormal changes including transient hypothyroidism (93%, 13/14), peak or hyperthyroidism (85%, 11/13) and euthyroidism (67%, 10/15) appeared within 6 months. The post-therapeutic stable euthyroid, hypothyroid or hyperthyroid state could be judged from the hormonal patterns in 57% (39/68) from 2.5 to 6 months, in 18% (12/68) from 6 to 9 months and in 25% (17/68) thereafter. CONCLUSION: Although the changes in thyroid hormones are not constant in Graves' disease during one year after 131I therapy, there are three basic patterns; valley, mountain and downhill patterns from one month after therapy. The post-therapeutic stable state can be judged by the hormonal level recovered from the bottom in most patients.

[Optimal phase of dynamic CT for detecting hypervascular hepatocellular carcinoma: evaluation of double arterial phases].

PURPOSE: To investigate the appropriate time of arterial phase for the detection of hypervascular hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Fifty-two hypervascular HCCs of 36 patients were evaluated on double arterial-phase images of the liver. The first and second arterial-phase images were obtained 10 sec after aortic peak enhancement time as determined by test bolus injection. Patients received a low or high concentration of contrast medium, according to their body weight, that was administered intravenously at a rate of 4 mL/sec and injection duration of 23 sec. Three radiologists evaluated the images separately. RESULTS: Sensitivity in detecting hypervascular HCCs was higher in the first arterial phase than in the second arterial phase (p = 0.039). HCCs were not detected as hypervascular nodules in one of 20 cases during 31 or fewer sec, or in 8 of 19 cases during 48 or more sec after the initiation of contrast medium injection. All nodules were detected as hypervascular lesions between 32 and 47 sec after the initiation of contrast medium injection. CONCLUSION: When a single arterial phase is obtained to detect hypervascular HCCs with a 23-sec injection time and an injection rate of 4 mL/sec, a protocol is recommended in which scanning is started at 35 sec and ended within 47 sec after initiating the injection of contrast medium.

[Guidelines for radio-iodine (131I) therapy in Graves' disease and thyroid cancer].

Radio-iodine (131I) therapy has been using in Graves' disease and well differentiated thyroid cancer. The rules of control in the discharge from radio-isotope hospital were notified in 1999 in Japan. Guideline of the 131I therapy in Graves' disease and thyroid cancer were prepared by sub-group of Japanese Society of Nuclear Medicine.

Characterization of adrenal tumors by chemical shift fast low-angle shot MR imaging: comparison of four methods of quantitative evaluation.

OBJECTIVE: The aim of our study was to assess quantitative methods of distinguishing adenomas from malignant adrenal lesions using chemical shift fast low-angle shot MR imaging. MATERIALS AND METHODS: We assessed 102 adrenal tumors in 88 patients (27 hyperfunctioning and 44 nonhyperfunctioning adenomas, 19 metastases, nine pheochromocytomas, and three other adrenal tumors) using chemical shift MR imaging. On the chemical shift imaging, signal intensity index, calculated as [(signal intensity on in-phase imaging - signal intensity on opposed-phase imaging) / (signal intensity on in-phase imaging)] x 100%, was compared with the adrenal-to-spleen ratio, adrenal-to-muscle ratio, and adrenal-to-liver ratio for signal change on opposed-phase fast low-angle shot MR imaging. The tissues in the spleen, paraspinal muscle, and liver were reference tissues. RESULTS: The signal intensity index had several advantages over the other three parameters calculated. We found no overlap in indexes between adenomas and metastatic tumors. The accuracy in distinguishing adenomas from metastatic tumors was 100% if the cutoff value of the signal intensity index selected was 11.2-16.5%. CONCLUSION: The signal intensity index is the most reliable evaluation method for differentiating adrenal adenomas from metastatic adrenal tumors.

Aldosteronomas: experience with superselective adrenal arterial embolization in 33 cases.

PURPOSE: To evaluate the effectiveness and long-term follow-up results of superselective adrenal arterial embolization (SAAE) of aldosteronomas. MATERIALS AND METHODS: Thirty-three patients with unilateral aldosteronomas were treated with SAAE. A 0.2-7.0-mL dose of high-concentration ethanol (HCE) was selectively infused into the feeding arterial branches of the aldosteronoma through a microcatheter by using a coaxial technique. Hormone, electrolyte, and blood pressure levels were evaluated after SAAE. The influence of background factors on SAAE success rate and the influence of age on hypertension in the patients in whom SAAE was successful were assessed with the Fisher exact test and a logistic regression model. RESULTS: SAAE was successful in 27 (82%) of 33 patients. SAAE success rate was not influenced by sex, age, hypertension duration, family history of hypertension, adenoma site, type of ethanol used, or number of embolized arteries. The destructive effects of SAAE continued for the 6-94-month (mean, 45 months) follow-up period in all patients in whom SAAE was successful. In one patient, aldosteronoma recurred 15 months after SAAE and the second SAAE was successful. Blood pressure decreased in all 11 (100%) patients aged 45 years or younger and in eight (50%) of 16 patients older than 45 years (P =.008). Blood pressure decreased within 4 weeks after SAAE in 15 (79%) of these 19 patients. The rate of blood pressure reduction after SAAE decreased with increasing age, and the correlation was significant (P =.022). None of the 33 patients had severe complications. CONCLUSION: SAAE with HCE is an effective therapy for aldosteronoma.

Scintigraphic progress of the liver in a patient with Alagille syndrome (arteriohepatic dysplasia).

We encountered a 9-year-old Japanese girl with Alagille syndrome. Her scintigraphic examinations of the liver were performed at the ages of 16 months and 9 years. 99mTc-PMT, a hepatobiliary imaging agent, was distributed homogeneously in the liver at the younger age, but unevenly produced an area of focally increased uptake in the medial segment of the liver surrounded by peripheral atrophy at the older age. 99mTc-GSA, a hepatoreceptor binding agent, was highly accumulated in the area, corresponding to the focally increased uptake of 99mTc-PMT. These imaging findings suggest that the pathophysiological and morphological changes of the liver occurred in our patient during the clinical course.